Lenovo Delivers Record Setting Q3 Performance With All Time Revenue And PTI Highs

Lenovo Group (HKSE: 992) (Pink Sheets: LNVGY) today announced Group revenue in the third quarter reached a record high of US$14.1 billion, and the tenth consecutive year-on-year quarter of growth. Pre-tax income grew 11% compared to the same quarter a year earlier, to US$390 million and net income also increased 11% year-on-year to US$258 million. Basic earnings per share for the third quarter were 2.16 US cents or 16.90 HK cents. “Last quarter, despite the geopolitical uncertainties and...

Lenovo Delivers Record Setting Q3 Performance With All Time Revenue And PTI Highs

Lenovo Group (HKSE: 992) (Pink Sheets: LNVGY) today announced Group revenue in the third quarter reached a record high of US$14.1 billion, and the tenth consecutive year-on-year quarter of growth. Pre-tax income grew 11% compared to the same quarter a year earlier, to US$390 million and net income also increased 11% year-on-year to US$258 million. Basic earnings per share for the third quarter were 2.16 US cents or 16.90 HK cents. “Last quarter, despite the geopolitical uncertainties and...

Lenovo Delivers Record Setting Q3 Performance With All Time Revenue And PTI Highs

Lenovo Group (HKSE: 992) (Pink Sheets: LNVGY) today announced Group revenue in the third quarter reached a record high of US$14.1 billion, and the tenth consecutive year-on-year quarter of growth. Pre-tax income grew 11% compared to the same quarter a year earlier, to US$390 million and net income also increased 11% year-on-year to US$258 million. Basic earnings per share for the third quarter were 2.16 US cents or 16.90 HK cents. “Last quarter, despite the geopolitical uncertainties and...

Lenovo Delivers Record Setting Q3 Performance With All Time Revenue And PTI Highs

Lenovo Group (HKSE: 992) (Pink Sheets: LNVGY) today announced Group revenue in the third quarter reached a record high of US$14.1 billion, and the tenth consecutive year-on-year quarter of growth. Pre-tax income grew 11% compared to the same quarter a year earlier, to US$390 million and net income also increased 11% year-on-year to US$258 million. Basic earnings per share for the third quarter were 2.16 US cents or 16.90 HK cents. “Last quarter, despite the geopolitical uncertainties and...

Galderma Announces New England Journal of Medicine Publication from Phase 2 Study of Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis

Galderma today announced that The New England Journal of Medicine (NEJM) has published full results from the Phase 2 study of its investigational therapy nemolizumab in adult patients suffering from moderate-to-severe prurigo nodularis (PN). PN is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus. It frequently leads to a severe quality of life impairment. Nemolizumab is a first-in-class investigational mo...

Galderma Announces New England Journal of Medicine Publication from Phase 2 Study of Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis

Galderma today announced that The New England Journal of Medicine (NEJM) has published full results from the Phase 2 study of its investigational therapy nemolizumab in adult patients suffering from moderate-to-severe prurigo nodularis (PN). PN is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus. It frequently leads to a severe quality of life impairment. Nemolizumab is a first-in-class investigational mo...

Galderma Announces New England Journal of Medicine Publication from Phase 2 Study of Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis

Galderma today announced that The New England Journal of Medicine (NEJM) has published full results from the Phase 2 study of its investigational therapy nemolizumab in adult patients suffering from moderate-to-severe prurigo nodularis (PN). PN is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus. It frequently leads to a severe quality of life impairment. Nemolizumab is a first-in-class investigational mo...

Galderma Announces New England Journal of Medicine Publication from Phase 2 Study of Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis

Galderma today announced that The New England Journal of Medicine (NEJM) has published full results from the Phase 2 study of its investigational therapy nemolizumab in adult patients suffering from moderate-to-severe prurigo nodularis (PN). PN is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus. It frequently leads to a severe quality of life impairment. Nemolizumab is a first-in-class investigational mo...

SES Responds to Intelsat’s Ex-parte Submission to the FCC Regarding the C-Band Spectrum Clearing Process

SES S.A. today notes the comments made by Intelsat in its ex-parte submission to the U.S. Federal Communication Commission (FCC) dated 19 February 2020. SES reaffirms its steadfast support for the Commission’s objectives to ensure global leadership in 5G, and it stands ready, willing, and able to play a central role in the expedited clearing of a portion of the C-band. SES believes that there remains an important role for the C-Band Alliance (CBA), and that the CBA’s collaborative clearin...

SES Responds to Intelsat’s Ex-parte Submission to the FCC Regarding the C-Band Spectrum Clearing Process

SES S.A. today notes the comments made by Intelsat in its ex-parte submission to the U.S. Federal Communication Commission (FCC) dated 19 February 2020. SES reaffirms its steadfast support for the Commission’s objectives to ensure global leadership in 5G, and it stands ready, willing, and able to play a central role in the expedited clearing of a portion of the C-band. SES believes that there remains an important role for the C-Band Alliance (CBA), and that the CBA’s collaborative clearin...